NCT05375370View on ClinicalTrials.gov

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA

NANot yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Hepatocellular Carcinoma

Interventions

OTHER

circulating tumor DNA dosage

blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma

All Listed Sponsors

lead

University Hospital, Rouen

OTHER

NCT05375370 - Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA | Biotech Hunter | Biotech Hunter